Two shareholders of Genzyme filed a lawsuit in federal court claiming that the company's board of directors is depriving them a chance "to receive maximum value for their shares" by not considering Sanofi-Aventis' $18.5 billion buyout offer. The shareholders requested that a judge order Genzyme to consider Sanofi's bid.

Related Summaries